Sumitomo Pharma
4506.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥453.3bn | ¥398.8bn | ¥314.6bn | ¥555.5bn | ¥560.0bn | ¥516.0bn |
| Operating income | ¥107.3bn | ¥28.8bn | −¥354.9bn | −¥77.0bn | ¥60.2bn | ¥71.2bn |
| Net income (owners) | ¥106.9bn | ¥23.6bn | −¥315.0bn | −¥74.5bn | ¥56.4bn | ¥56.2bn |
| Total assets | ¥804.6bn | ¥742.6bn | ¥907.5bn | ¥1.13T | ¥1.31T | ¥1.31T |
| Net assets / equity | ¥292.5bn | ¥169.5bn | ¥156.1bn | ¥406.8bn | ¥673.6bn | ¥648.2bn |
| Operating cash flow | ¥71.7bn | ¥16.5bn | −¥241.9bn | ¥11.9bn | ¥31.2bn | ¥135.6bn |
| EPS (basic) | ¥268.99 | ¥59.49 | ¥-792.79 | ¥-187.55 | ¥141.99 | ¥141.5 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 1
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 190 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Asia | ¥23.0bn | ¥9.5bn |
| Japan | ¥92.4bn | ¥12.4bn |
| North America | ¥337.9bn | ¥75.7bn |
| Total | ¥453.3bn | ¥97.5bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.